Your browser doesn't support javascript.
loading
Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.
Attarbaschi, Andishe; Carraro, Elisa; Ronceray, Leila; Andrés, Mara; Barzilai-Birenboim, Shlomit; Bomken, Simon; Brugières, Laurence; Burkhardt, Birgit; Ceppi, Francesco; Chiang, Alan K S; Csoka, Monika; Fedorova, Alina; Jazbec, Janez; Kabickova, Edita; Loeffen, Jan; Mellgren, Karin; Miakova, Natalia; Moser, Olga; Osumi, Tomoo; Pourtsidis, Apostolos; Rigaud, Charlotte; Uyttebroeck, Anne; Woessmann, Wilhelm; Pillon, Marta.
Afiliación
  • Attarbaschi A; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria. andishe.attarbaschi@stanna.at.
  • Carraro E; Department of Pediatric Hematology and Oncology, University of Padova, Padova, Italy.
  • Ronceray L; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
  • Andrés M; Department of Pediatric Hematology and Oncology, University La Fe Hospital, Valencia, Spain.
  • Barzilai-Birenboim S; Department of Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel.
  • Bomken S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Brugières L; Wolfson Childhood Cancer Center, Newcastle University, Newcastle, UK.
  • Burkhardt B; Department of Pediatric and Adolescent Oncology, Gustave-Roussy Cancer Center, Paris-Saclay University, Villejuif, France.
  • Ceppi F; Pediatric Hematology and Oncology, University-Hospital of Münster, Münster, Germany.
  • Chiang AKS; Pediatric Hematology-Oncology Research Laboratory & Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland.
  • Csoka M; Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
  • Fedorova A; Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary.
  • Jazbec J; Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
  • Kabickova E; Division of Pediatrics, Hematology and Oncology, University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Loeffen J; Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Mellgren K; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Miakova N; Department of Pediatric Hematology and Oncology, The Queen Silvia's Hospital for Children and Adolescents, University of Gothenburg, Gothenburg, Sweden.
  • Moser O; Department of Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Osumi T; Department of Pediatric Hematology and Oncology, Rheinisch-Westfälische Technische Hochschule (RWTH)-Aachen University, Aachen, Germany.
  • Pourtsidis A; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Rigaud C; Department of Oncology, "P & A. Kyriakou" Children's Hospital, Athens, Greece.
  • Uyttebroeck A; Department of Pediatric and Adolescent Oncology, Gustave-Roussy Cancer Center, Paris-Saclay University, Villejuif, France.
  • Woessmann W; Department of Pediatric Hematology and Oncology, University Hospital Leuven, Leuven, Belgium.
  • Pillon M; Department of Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Leukemia ; 35(2): 534-549, 2021 02.
Article en En | MEDLINE | ID: mdl-32393843
Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin's lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) "other" SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 ± 4%, being worst for patients with preexisting disorders at 28 ± 8%. Five-year OS rates were 38 ± 8%, 59 ± 7%, 79 ± 8%, 34 ± 12%, and 62 ± 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and "other" SMNs (p < 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Neoplasias Primarias Secundarias / Trasplante de Células Madre / Quimioradioterapia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Neoplasias Primarias Secundarias / Trasplante de Células Madre / Quimioradioterapia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article